# Ipsen: Phase 1 study closed enrollment, 6 enrolled (Low-grade Glioma)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Ipsen |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours |
| NCT ID | NCT07441707 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Low-grade Glioma |
| Intervention types | drug |
| Target enrollment | 6 |
| Site countries | Japan |
| Posted | 2026-03-02 |
| Planned start | 2026-03-10 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-01 |
| Last update posted | 2026-10-01 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07441707). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.